Qube Research & Technologies (QRT)
ENGN icon

Qube Research & Technologies (QRT)’s enGene Therapeutics ENGN Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$346K Buy
+200,187
New +$816K ﹤0.01% 2750
2024
Q2 		– Sell
-14
Closed -$237 – 4040
2024
Q1 		$237 Buy
+14
New +$171 ﹤0.01% 4128

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ENGN Position: Q2 2026 in Review

Qube Research & Technologies (QRT) opened a new position in enGene Therapeutics (ENGN) in Q2 2026: 200,187 shares worth $346K. The stake represents ﹤0.01% of the portfolio and ranks #2750 among its holdings. This is a return to the name: Qube Research & Technologies (QRT) previously reported a position in ENGN as recently as Q1 2024.

Qube Research & Technologies (QRT) first reported a position in ENGN in Q1 2024 and has held it in 2 quarters since. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Qube Research & Technologies (QRT) held 200,187 shares of enGene Therapeutics worth $346K as of Q2 2026.
  • enGene Therapeutics was a new Qube Research & Technologies (QRT) position in Q2 2026.
  • enGene Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #2750 holding.
  • Qube Research & Technologies (QRT) first reported a position in enGene Therapeutics in Q1 2024 and has held it in 2 quarters since.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.